Context Therapeutics Partners With Integral Molecular To Develop An Emerging Cancer Drug
Context Therapeutics Inc. (NASDAQ: CNTX) and Integral Molecular are teaming up to develop an anti-claudin 6 (CLDN6) bispecific monoclonal antibody (BsMAb) for cancer therapy.
